Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Pfizer
Stanford University
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
Rhizen Pharmaceuticals SA
Northwestern University
Mayo Clinic
Case Comprehensive Cancer Center
Massachusetts General Hospital
TetraLogic Pharmaceuticals